WS #17028
Humana shares spiked after reporting better-than-expected Q3 2026 results, driven by its CenterWell unit. In the pharmaceutical space, Eli Lilly partnered with telehealth platform Hims & Hers to offer its obesity medications Zepbound and Foundayo, intensifying competition with Novo Nordisk. These developments highlight consolidation and distribution expansion in the healthcare sector.
Healthcare and Biotech Developments
Humana shares spiked after reporting better-than-expected Q3 2026 results, driven by its CenterWell unit. In the pharmaceutical space, Eli Lilly partnered with telehealth platform Hims & Hers to offer its obesity medications Zepbound and Foundayo, intensifying competition with Novo Nordisk. These developments highlight consolidation and distribution expansion in the healthcare sector.